BAY 41-6551 adjunctive aerosolized amikacin for mechanically ventilated Gram-negative pneumonia

Phase 3, randomised, double-blind trial comparing BAY 41-6551 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoints: Clinical response at Test-of-Cure and Safety and adverse events. Started Jun 2014; status: active, not recruiting.